Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Governance Documents Committees Year None20232022 May 31, 2023 Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day May 25, 2023 Biohaven to Present R&D Day at Yale School of Management May 12, 2023 Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments April 17, 2023 Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy March 23, 2023 Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments March 22, 2023 Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders March 14, 2023 Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting February 21, 2023 Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy January 6, 2023 Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed.
Year None20232022 May 31, 2023 Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day May 25, 2023 Biohaven to Present R&D Day at Yale School of Management May 12, 2023 Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments April 17, 2023 Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy March 23, 2023 Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments March 22, 2023 Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders March 14, 2023 Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting February 21, 2023 Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy January 6, 2023 Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
May 31, 2023 Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
May 12, 2023 Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
April 17, 2023 Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
March 23, 2023 Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
March 22, 2023 Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
March 14, 2023 Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
February 21, 2023 Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
